DXCM MEXC RealStocks
Own real DXCM shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-19 02:28:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
DexCom, Inc. (DXCM) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $82.53, with a market capitalization of $30.44B and a P/E ratio of 30.87. Over the past 52 weeks, its price has ranged from $56.72 to $92.59. This page covers its latest market performance, valuation, price trends and company information.
$30.44B | |
$81.67 | |
$83.15 | |
$81.40 | |
$82.04 | |
2.86M | |
4.18M | |
30.87 | |
$92.59 | |
$56.72 | |
-- | |
2026-09-30 |
DexCom, Inc. (DXCM) last closed at $82.53 as of 2026-11-19 00:58:00, up 0.57% ($0.47) from the previous close of $82.04.
During the latest regular trading session, DXCM traded between $81.40 and $83.15, with a volume of 2.86M shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, DexCom, Inc. (DXCM) moved from $81.07 to $82.53, representing a gain of 1.80% ($1.46).
The stock traded between $78.93 and $84.02 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 3.78 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 72.0%
DXCM is currently trading at $82.53, placing it 72.0% of the way from its 52-week low of $56.72 to its 52-week high of $92.59. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 11,100 |
| CEO | Jacob Steven Leach |
| Founded | 1999 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of DexCom, Inc. (DXCM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to DXCM, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between DXCM shares and USD.
DXCM Shares to USD
1.00 DXCM shares = 82.529 USD
Calculations are estimates based on the latest available price and are for reference only.